Target Price | $20.40 |
Price | $7.81 |
Potential |
161.20%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Enanta Pharmaceuticals, Inc. 2026 .
The average Enanta Pharmaceuticals, Inc. target price is $20.40.
This is
161.20%
register free of charge
$26.25
236.11%
register free of charge
$7.07
9.48%
register free of charge
|
|
A rating was issued by 12 analysts: 9 Analysts recommend Enanta Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Enanta Pharmaceuticals, Inc. stock has an average upside potential 2026 of
161.20%
register free of charge
|
Sep '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 67.64 | 67.23 |
14.60% | 0.60% | |
EBITDA Margin | -176.46% | -138.06% |
3.66% | 21.76% | |
Net Margin | -171.57% | -129.16% |
1.56% | 24.72% |
7 Analysts have issued a sales forecast Enanta Pharmaceuticals, Inc. 2025 . The average Enanta Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Enanta Pharmaceuticals, Inc. EBITDA forecast 2025. The average Enanta Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Enanta Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Enanta Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Sep '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -5.49 | -4.06 |
13.95% | 26.05% | |
P/E | negative | |
EV/Sales | negative |
9 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast for earnings per share. The average Enanta Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Enanta Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Evercore ISI Group |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
WestPark Capital |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 24 2024 |
Analyst Rating | Date |
---|---|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Sep 15 2025 |
Locked
WestPark Capital:
Locked
➜
Locked
|
Sep 02 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 12 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Jun 03 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 11 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Feb 11 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 24 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.